CliffBio
small molecule

DIACOMIT

STIRIPENTOL

Loss of exclusivityJuly 2029FDA regulatory exclusivity expiry
CompanyBiocodex →See this company's full patent-cliff portfolio

Drug detail

Brand nameDIACOMIT
Active ingredientSTIRIPENTOL
Strength500MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2018
Marketing statusRX

Regulatory exclusivity

CodeExpires
ODE-403July 2029

More from Biocodex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.